PURPOSE: Bone is the most common site of metastases from nasopharyngeal carcinoma (NPC). Zoledronic acid (ZA) used to prevent skeletal-related events (SREs) of bone metastases has shown anti-tumor effects; yet, no report has been found on the survival benefit of ZA in NPC. This study aimed to evaluate whether ZA can bring survival benefits to patients with bone metastases from NPC. METHODS: A total of 307 patients with of NPC who had bone metastases were analyzed retrospectively. The differences of survival between patients treated with chemotherapy combined with ZA and those with chemotherapy alone were evaluated by the log-rank test. The Cox multivariate analyses of clinical features and different treatment methods of the 307 patients were conducted. RESULTS: The prevalence of SREs in the combined approach group was lower than that with chemotherapy alone (34% vs. 48%, X (2) = 7.003, P = 0.008). The combined approach group had better progression-free survival (PFS) (11.5 vs. 5.5 months, P < 0.001) and overall survival (OS) (23.5 vs. 17.5 months, P < 0.001) than chemotherapy alone group. Cox multivariate analysis identified the following independent prognostic factors: ZA treatment, bone metastatic sites, baseline serum alkaline phosphatase (ALP) level, SREs and cycles of chemotherapy. CONCLUSIONS: ZA treatment combined with chemotherapy could reduce SREs and improve PFS and OS for NPC patients with bone metastases.
PURPOSE: Bone is the most common site of metastases from nasopharyngeal carcinoma (NPC). Zoledronic acid (ZA) used to prevent skeletal-related events (SREs) of bone metastases has shown anti-tumor effects; yet, no report has been found on the survival benefit of ZA in NPC. This study aimed to evaluate whether ZA can bring survival benefits to patients with bone metastases from NPC. METHODS: A total of 307 patients with of NPC who had bone metastases were analyzed retrospectively. The differences of survival between patients treated with chemotherapy combined with ZA and those with chemotherapy alone were evaluated by the log-rank test. The Cox multivariate analyses of clinical features and different treatment methods of the 307 patients were conducted. RESULTS: The prevalence of SREs in the combined approach group was lower than that with chemotherapy alone (34% vs. 48%, X (2) = 7.003, P = 0.008). The combined approach group had better progression-free survival (PFS) (11.5 vs. 5.5 months, P < 0.001) and overall survival (OS) (23.5 vs. 17.5 months, P < 0.001) than chemotherapy alone group. Cox multivariate analysis identified the following independent prognostic factors: ZA treatment, bone metastatic sites, baseline serum alkaline phosphatase (ALP) level, SREs and cycles of chemotherapy. CONCLUSIONS:ZA treatment combined with chemotherapy could reduce SREs and improve PFS and OS for NPC patients with bone metastases.
Authors: Albiruni R A Razak; Lillian L Siu; Fei-Fei Liu; Emma Ito; Brian O'Sullivan; Kelvin Chan Journal: Eur J Cancer Date: 2010-05-05 Impact factor: 9.162
Authors: Y Bensouda; W Kaikani; N Ahbeddou; R Rahhali; M Jabri; H Mrabti; H Boussen; H Errihani Journal: Eur Ann Otorhinolaryngol Head Neck Dis Date: 2010-12-21 Impact factor: 2.080
Authors: Guru Sonpavde; Gregory R Pond; William R Berry; Ronald de Wit; Andrew J Armstrong; Mario A Eisenberger; Ian F Tannock Journal: Urol Oncol Date: 2010-10-02 Impact factor: 3.498
Authors: Penelope D Ottewell; Hannu Mönkkönen; Mark Jones; Diane V Lefley; Robert E Coleman; Ingunn Holen Journal: J Natl Cancer Inst Date: 2008-08-11 Impact factor: 13.506
Authors: Salvatore Grisanti; Susanna Bianchi; Laura D Locati; Luca Triggiani; Stefania Vecchio; Alberto Bonetta; Cristiana Bergamini; Pierfranco Conte; Mario Airoldi; Marco Merlano; Paolo Carlini; Toni Ibrahim; Ciro Rossetto; Salvatore Alfieri; Paolo Pronzato; Sandro Tonoli; Roberto Maroldi; Piero Nicolai; Carlo Resteghini; Stefano M Magrini; Alfredo Berruti Journal: PLoS One Date: 2019-03-20 Impact factor: 3.240